Zenagamtide (GLP-1/Amylin): 10mg

Description

Zenagamtide — formerly known as amycretin, novo nordisk development code nn9487 — is an investigational unimolecular peptide that simultaneously activates the glucagon-like peptide-1 (glp-1) receptor, the amylin receptor, and the calcitonin receptor. the compound's design addresses a structural property of the amylin receptor itself: the amylin receptor is a heterodimer formed by the calcitonin receptor paired with a receptor-activity-modifying protein (ramp), which means that glp-1 and amylin co-agonism in a single peptide chain inherently extends to calcitonin receptor activation. this places zenagamtide in a mechanistically distinct position from cagrisema, which achieves glp-1/amylin co-activation by combining two separate molecules (cagrilintide + semaglutide). phase 2 subcutaneous trial data published in the lancet (august 15, 2026; pmid 42532080) showed once-weekly zenagamtide across a dose range of 0.4–40mg in adults with type 2 diabetes produced up to 14.6% body weight reduction and hba1c reductions of up to 1.71 percentage points at 36 weeks, with 89.1% of participants achieving hba1c below 7% at the highest dose. earlier phase 1b/2a data in adults with obesity without type 2 diabetes showed up to 24.3% mean body weight reduction at 36 weeks — a result exceeding approved glp-1 monotherapy at comparable timepoints. tolerability profile in both trials was consistent with other glp-1-based and amylin-based therapies, predominantly gastrointestinal. a companion phase 2 trial of an oral zenagamtide formulation was also published in the lancet on the same date (piis0140-6736(26)01247-x). novo nordisk announced phase 3 programs — amaze (obesity indication) and ambition (type 2 diabetes) — for initiation in h2 2026. zenagamtide is not fda approved and is not available outside authorised clinical trials as of august 2026. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.

Specifications

Dose Calculator